Silvia de la Iglesia

Silvia de la Iglesia

Auto-generated profile, based on publicly available information

Silvia de la Iglesia

Department of Hematology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ADAdrián SEGURA DIAZ
Adrián SEGURA DIAZ
RSRuth Stuckey
Ruth Stuckey
YFYanira Florido
Yanira Florido
JGJesús González-Martín
Jesús González-Martín
JLJuan Francisco López-Rodríguez
Juan Francisco López-Rodríguez
CSCristina Bilbao Sieyro
Cristina Bilbao Sieyro
The development of thrombotic events is common among patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We studied the influence of pathogenic mutations frequently associated with myeloid malignancies on thrombotic events using next-generation sequencing (NGS) in an initial cohort of 68 patients with myeloproliferative neoplasms (MPN). As expected, the presence of mutations in DNMT3A, TET2, and ASXL1 (DTA genes) was positively associated with age for the whole cohort (p = 0.025, OR: 1.047, 95% CI: 1.006–1.090). Also, while not related with events in the whole cohort, DTA mutations were strongly associated with the development of vascular events in PV patients (p = 0.028). To confirm the possible association between the presence of DTA mutation and thrombotic events, we performed a case-control study on 55 age-matched patients with PV (including 12 PV patients from the initial cohort, 25 with event vs. 30 no event). In the age-matched case-control PV cohort, the presence of ≥1 DTA mutation significantly increased the risk of a thrombotic event (OR: 6.333, p = 0.0024). Specifically, mutations in TET2 were associated with thrombotic events in the PV case-control cohort (OR: 3.56, 95% CI: 1.15–11.83, p = 0.031). Our results suggest that pathogenic DTA mutations, and particularly TET2 mutations, may be an independent risk factor for thrombosis in patients with PV. However, the predictive value of TET2 and DTA mutations in ET and PMF was inconclusive and should be determined in a larger cohort.

22 June 2014 in Journal of Diabetes Science and Technology
Verified
Journal Article
Open access
MLMercedes Lorenzo-Medina
Mercedes Lorenzo-Medina
SDSilvia De-La-Iglesia
Silvia De-La-Iglesia
PRPaloma Ropero
Paloma Ropero
PNPatricia Nogueira-Salgueiro
Patricia Nogueira-Salgueiro
JSJesus Santana-Benitez
Jesus Santana-Benitez
Background: Hemoglobin A1c (HbA1c) is routinely used to monitor long-term glycemic control and for diagnosing diabetes mellitus. However, hemoglobin (Hb) gene variants/modifications can affect the accuracy of some methods. The potential effect of Hb variants on HbA1c measurements was investigated using a high-performance liquid chromatography (HPLC) method compared with an immunoturbimetric assay. Methods: Fasting plasma glucose (FPG) and HbA1c levels were measured in 42 371 blood samples. Samples producing abnormal chromatograms were further analyzed to characterize any Hb variants. Fructosamine levels were determined in place of HbA1c levels when unstable Hb variants were identified. Results: Abnormal HPLC chromatograms were obtained for 160 of 42 371 samples. In 26 samples HbS was identified and HbA1c results correlated with FPG. In the remaining 134 samples HbD, Hb Louisville, Hb Las Palmas, Hb N-Baltimore, or Hb Porto Alegre were identified and HbA1c did not correlate with FPG. These samples were retested using an immunoturbidimetric assay and the majority of results were accurate; only 3 (with the unstable Hb Louisville trait) gave aberrant HbA1c results. Conclusions: Hb variants can affect determination of HbA1c levels with some methods. Laboratories should be aware of Hb variants occurring locally and choose an appropriate HbA1c testing method.

1 June 2009 in Leukemia Research
Verified
Journal Article
Closed access
SISilvia De la Iglesia Iñigo
Silvia De la Iglesia Iñigo
CLCarmen Elsa López-Jorge
Carmen Elsa López-Jorge
MCMaría Teresa Gómez Casares
María Teresa Gómez Casares
ACAngelina Lemes Castellano
Angelina Lemes Castellano
PCPedro Martín Cabrera
Pedro Martín Cabrera
TLTeresa Molero Labarta
Teresa Molero Labarta

28 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSCristina Bilbao Sieyro
Cristina Bilbao Sieyro
GSGuillermo Santana
Guillermo Santana
MMMelania Moreno
Melania Moreno
LTLaura Torres
Laura Torres
GSGonzalo Santana-Lopez
Gonzalo Santana-Lopez
MCMaría Teresa Gómez Casares
María Teresa Gómez Casares
The recent discovery of CALR mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients without JAK2/MPL mutations has emerged as a relevant finding for the molecular diagnosis of these myeloproliferative neoplasms (MPN). We tested the feasibility of high-resolution melting (HRM) as a screening method for rapid detection of CALR mutations. CALR was studied in wild-type JAK2/MPL patients including 34 ET, 21 persistent thrombocytosis suggestive of MPN and 98 suspected secondary thrombocytosis. CALR mutation analysis was performed through HRM and Sanger sequencing. We compared clinical features of CALR-mutated versus 45 JAK2/MPL-mutated subjects in ET. Nineteen samples showed distinct HRM patterns from wild-type. Of them, 18 were mutations and one a polymorphism as confirmed by direct sequencing. CALR mutations were present in 44% of ET (15/34), 14% of persistent thrombocytosis suggestive of MPN (3/21) and none of the secondary thrombocytosis (0/98). Of the 18 mutants, 9 were 52 bp deletions, 8 were 5 bp insertions and other was a complex mutation with insertion/deletion. No mutations were found after sequencing analysis of 45 samples displaying wild-type HRM curves. HRM technique was reproducible, no false positive or negative were detected and the limit of detection was of 3%. This study establishes a sensitive, reliable and rapid HRM method to screen for the presence of CALR mutations.

28 January 2017 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
SISilvia De‐ La‐ Iglesia‐ Iñigo
Silvia De‐ La‐ Iglesia‐ Iñigo
MMMaría‐Isabel Moreno‐Carralero
María‐Isabel Moreno‐Carralero
ALAngelina Lemes‐Castellano
Angelina Lemes‐Castellano
TMTeresa Molero‐Labarta
Teresa Molero‐Labarta
MMManuel Méndez
Manuel Méndez
MMMaría-Josefa Morán-Jiménez
María-Josefa Morán-Jiménez
Key Clinical Message: Congenital dyserythropoietic anemias (CDAs) are displayed by ineffective erythropoiesis. The wide variety of phenotypes observed in CDA patients makes differential diagnosis difficult; identification of the genetic variants is crucial in clinical management. We report the fifth case of a patient with unclassified CDAs, after genetic study, with CDA type IV.

1 January 2002 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MCMaría Teresa Gómez Casares
María Teresa Gómez Casares
SISilvia de la Iglesia
Silvia de la Iglesia
MPMaria Perera
Maria Perera
ALAngelina Lemes
Angelina Lemes
CCConrado Campo
Conrado Campo
TMTeresa Molero
Teresa Molero
It has been demonstrated that some myeloid blasts express renin, but normal bone marrow (BM) does not display this expression. The aim of the present work was to analyze the renin expression in different hematological malignancies and different myeloid cell lines. We investigated the expression of renin by RT-PCR in BM from patients with hematological malignancies (106 patients), in nine normal BM from healthy donors and in leukemic cell lines (K562, KU812, MEG-01, U-937 and HL60), as well in K562 cell line subjected to differentiation treatments. We have observed renin expression in cells from acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) cases. The highest frequency was observed in AML-non acute promyelocytic leukemia(APL) cases (47.2% of the cases). The disappearance of this expression was associated with the status of complete remission of AML. Renin is expressed in some myeloid human leukemia cell lines such as K562, KU812 and MEG-01. However, when K562 cells were treated with inducers of growth inhibition and/or differentiation, the expression did not disappear, indicating that renin expression is associated with a blastic phenotype rather than with cell proliferation. The obtained findings suggest that the renin expression could have a role on the disease development and could be used as an aberrant marker of leukemia.